Showing results (341-350 of 407) with videos related to

Sort By:
Pageof 41
Molecular Endocrinology (Baltimore, Md.)|January 15, 2013
Research resource: tissue- and pathway-specific metabolomic profiles of the steroid receptor coactivator (SRC) familyBrian York, Jørn V Sagen, Anna Tsimelzon, et al.
Breast Cancer Research and Treatment|May 1, 2007
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patientsJenny C Chang, Andreas Makris, M Carolina Gutierrez, et al.
Cancer Research Communications|February 14, 2022
Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeuticsYang Gao, Elena B Kabotyanski, Jonathan H Shepherd, et al.
Clinical Breast Cancer|November 13, 2017
Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27Polly Niravath, Bingshu Chen, Judy-Anne W Chapman, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
Rat somatic genome editing enables ER+ breast cancer modelingWen Bu, Tobie Lee, Meenakshi Anurag, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast CancerXian Wang, Jamunarani Veeraraghavan, Chia-Chia Liu, et al.
Cell Research|May 31, 2014
An epigenomic approach to therapy for tamoxifen-resistant breast cancerQin Feng, Zheng Zhang, Martin J Shea, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 2, 2022
High viral loads: what drives fatal cases of COVID-19 in vaccinees? - an autopsy studyKlaus Hirschbühl, Tina Schaller, Bruno Märkl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancerM L Rothenberg, J R Eckardt, J G Kuhn, et al.
British Journal of Cancer|December 18, 2018
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistanceAgostina Nardone, Hazel Weir, Oona Delpuech, et al.
Pageof 41